12/10
07:37 am
cybn
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results [Yahoo! Finance]
Low
Report
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results [Yahoo! Finance]
12/10
07:30 am
cybn
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Low
Report
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
12/4
02:04 pm
cybn
Facet Life Sciences Named Regulatory Partner for Cybin's Neuropsychiatry Therapeutics Development Pipeline [Yahoo! Finance]
Low
Report
Facet Life Sciences Named Regulatory Partner for Cybin's Neuropsychiatry Therapeutics Development Pipeline [Yahoo! Finance]
12/4
07:30 am
cybn
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
Low
Report
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
11/18
12:36 pm
cybn
Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Medium
Report
Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
11/18
07:12 am
cybn
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder [Yahoo! Finance]
High
Report
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder [Yahoo! Finance]
11/18
07:00 am
cybn
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
High
Report
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
11/14
11:13 am
cybn
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $96.00 to $86.00. They now have a "buy" rating on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $96.00 to $86.00. They now have a "buy" rating on the stock.
11/14
07:30 am
cybn
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Low
Report
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
11/13
07:30 am
cybn
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
High
Report
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
10/31
07:30 am
cybn
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
Low
Report
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
10/24
07:30 am
cybn
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
Low
Report
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
10/24
07:13 am
cybn
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program [Yahoo! Finance]
Low
Report
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program [Yahoo! Finance]
10/15
12:31 pm
cybn
Cybin: Top Value Psychedelic Stock [Seeking Alpha]
Low
Report
Cybin: Top Value Psychedelic Stock [Seeking Alpha]